SCHEMBL5037356

SCHEMBL5037356

COCC1CCCN1c1cc(C)nc2cc(O)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 14/20 0.41
ADORA1 P30542 12/20 0.41
CRHR1 P34998 1/20 0.40
CYP1A2 P05177 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2B P29275 1/20 0.40
CTNNB1 P35222 1/20 0.40
TCF7L2 Q9NQB0 1/20 0.40
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
CDC42BPB Q9Y5S2 1/20 0.39
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
RAD52 P43351 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037350 1.00 ADORA2A (0.41) ADORA2AADORA1CRHR1CYP1A2ADORA3
SCHEMBL5036101 0.87 MAP2K7 (0.48) ADORA2AADORA1ADORA3ADORA2BKDM4E
SCHEMBL5036104 0.87 MAP2K7 (0.48) ADORA2AADORA1ADORA3ADORA2BKDM4E
SCHEMBL5022604 0.87 ADORA2A (0.46) ADORA2AADORA1CRHR1CYP1A2ADORA3
SCHEMBL5026872 0.87 ADORA2A (0.41) ADORA2AADORA1CRHR1CYP1A2ADORA3
SCHEMBL5026828 0.87 ADORA2A (0.41) ADORA2AADORA1CRHR1CYP1A2ADORA3
SCHEMBL5026832 0.87 ADORA2A (0.41) ADORA2AADORA1CRHR1CYP1A2ADORA3
SCHEMBL5091471 0.87 ADORA2A (0.46) ADORA2AADORA1CRHR1CYP1A2ADORA3
SCHEMBL5040496 0.83 ADORA2A (0.39) ADORA2AADORA1CRHR1CTNNB1TCF7L2
SCHEMBL6369357 0.83 ADORA2A (0.39) ADORA2AADORA1CRHR1CTNNB1TCF7L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395564-B1 QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR HOFFMANN LA ROCHE (CH) 2008-02-27 EP disclosed
US-20050049413-A1 Quinoline derivatives MUELLER WERNER (CH) 2005-03-03 US disclosed
US-6818767-B2 NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY HOFFMANN-LA ROCHE INC. 2004-11-16 US disclosed
US-20020198194-A1 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198194-A1 Quinoline derivatives NPY2R, NPY1R, NPY4R ADORA2A 2125/4885ADORA1 1794/4885CRHR1 77/4885
US-20050049413-A1 Quinoline derivatives NPY2R, NPY1R, NPY4R ADORA2A 2125/4885ADORA1 1794/4885CRHR1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.